Australian Clinical Labs Ltd (ASX: ACL) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Australian Clinical Labs Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $597.69 million
P/E Ratio 19.63
Dividend Yield 4.15%
Shares Outstanding 198.57 million
Earnings per share 0.153
Dividend per share 0.13
Year To Date Return -11.48%
Earnings Yield 5.09%
Franking 100%
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

Australian Clinical Labs Ltd (ASX: ACL)
Latest News

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Boys making faces and flexing.
Share Market News

3 ASX All Ords shares with 'potential for strong future performance'

Tamim Asset Management reveals 3 ASX All Ords shares that are primed for growth.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

ASX All Ords share higher despite major shareholder cashing out 30% stake

Investors in this ASX All Ords healthcare share appear unperturbed by news of a major sell-down.

Read more »

a man holds his arms out and shrugs his shoulders as if indicating he doesn't know the answer to a question he's been asked.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

The words short selling in red against a black background
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A business woman looks unhappy while she flies a red flag at her laptop.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Close up of a sad young woman reading about declining share price on her phone.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A business woman looks unhappy while she flies a red flag at her laptop.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Scared, wide-eyed man in pink t-shirt with hands covering mouth
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A woman in an office is being pressured, she rubs her temples from the stress.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Cheap Shares

'Undervalued': 3 ASX 300 shares to buy following significant share price falls

Experts have named these ASX shares as buys.

Read more »

most shorted ASX shares
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Frequently Asked Questions

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
27 Mar 2025 $0.0350 100.00% Interim 16 Apr 2025
04 Sep 2024 $0.0900 100.00% Final 27 Sep 2024
28 Mar 2024 $0.0300 100.00% Interim 26 Apr 2024
27 Mar 2023 $0.0700 100.00% Interim 26 Apr 2023
23 Aug 2022 $0.4100 100.00% Final 15 Sep 2022
25 Mar 2022 $0.1200 100.00% Interim 21 Apr 2022

ACL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Australian Clinical Labs Ltd

Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.

Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing. 

In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.

ACL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
24 Apr 2025 $3.01 $0.06 2.03% 759,629 $2.96 $3.03 $2.95
23 Apr 2025 $2.95 $0.02 0.68% 657,163 $2.95 $2.99 $2.93
22 Apr 2025 $2.93 $-0.07 -2.33% 421,338 $3.00 $3.00 $2.91
17 Apr 2025 $3.00 $0.00 0.00% 2,049,343 $3.00 $3.02 $2.96
16 Apr 2025 $3.00 $0.02 0.67% 739,215 $3.00 $3.06 $2.97
15 Apr 2025 $2.98 $0.03 1.02% 331,615 $2.97 $2.99 $2.95
14 Apr 2025 $2.95 $-0.02 -0.67% 306,562 $3.00 $3.00 $2.93
11 Apr 2025 $2.97 $-0.07 -2.30% 313,361 $3.00 $3.00 $2.93
10 Apr 2025 $3.04 $0.13 4.47% 678,966 $3.06 $3.10 $3.00
09 Apr 2025 $2.91 $-0.15 -4.90% 1,684,874 $3.05 $3.05 $2.90
08 Apr 2025 $3.06 $0.21 7.37% 829,304 $2.88 $3.07 $2.81
07 Apr 2025 $2.85 $-0.08 -2.73% 715,848 $2.88 $2.90 $2.81
04 Apr 2025 $2.93 $-0.09 -2.98% 2,333,270 $2.91 $3.00 $2.91
03 Apr 2025 $3.02 $0.02 0.67% 571,706 $2.91 $3.03 $2.91
02 Apr 2025 $3.00 $0.00 0.00% 1,184,576 $2.99 $3.01 $2.97
01 Apr 2025 $3.00 $0.02 0.67% 578,371 $3.01 $3.01 $2.92
31 Mar 2025 $2.98 $0.01 0.34% 528,982 $2.95 $3.00 $2.93
28 Mar 2025 $2.97 $-0.03 -1.00% 512,130 $3.00 $3.02 $2.95
27 Mar 2025 $3.00 $-0.04 -1.32% 744,379 $2.98 $3.06 $2.98

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
26 Aug 2024 Melinda McGrath Expiry 247,252 $694,778
As advised by the company. forfeited

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Michael Thomas Alscher Non-Executive DirectorNon-Executive Chairman Dec 2020
Mr Alscher is the Managing Partner and founder of Crescent, an Australian private equity investment firm, specialising in high growth companies and certain industry sectors such as healthcare. Michael is the current Chair of Cardno Limited, National Dental Care Limited, 24-7 Healthcare Pty Ltd and is a Non-Executive Director of Clearview Wealth Limited, Green Leaves Early Learning Centres Pty Ltd and Aurora Expeditions Holdings Pty Ltd. Michael's former director roles include Chair of Cover-More Group Limited, LifeHealthcare Group Limited and Director of Metro Performance Glass Limited, Crumpler Pty Ltd and Intega Group Limited. Prior to founding Crescent in 2000, Michael was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles. Michael is a Member of Risk Committee.
Dr Leanne Rowe Non-Executive Director Apr 2021
Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Leanne is currently a Non-Executive Director of Bupa ANZ Group and a Presiding Member for Medical Panels Victoria. She has previously served on a range of boards, including as a Chair of Nexus Hospitals, the Royal Australian College of General Practitioners and Barwon Health (Acting); and as a Non-Executive Director of Japara Healthcare, Medibank Private, I-Med Radiology, the Medical Indemnity Protection Society and Beyond Blue. Leanne is a former Deputy Chancellor of Monash University. Leanne Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Leanne is currently a Non-Executive Director of Bupa ANZ Group and a Presiding Member for Medical Panels Victoria. She has previously served on a range of boards, including as a Chair of Nexus Hospitals, the Royal Australian College of General Practitioners and Barwon Health (Acting); and as a Non-Executive Director of Japara Healthcare, Medibank Private, I-Med Radiology, the Medical Indemnity Protection Society and Beyond Blue. Leanne is a former Deputy Chancellor of Monash University. Leanne
Ms Christine Nildra Bartlett Non-Executive Director Aug 2023
Ms Bartlett is an experienced Non-Executive Director, with executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a commercial perspective, in fostering innovation and leveraging new emerging technologies. Christine is currently a Non-Executive Director of Mirvac Limited, TAL Life Limited and Reliance Worldwide Corporation Limited. Christine is a member of the UNSW Australian School of Business Advisory Council, Chief Executive Women and the Australian Institute of Company Directors. Christine has previously held Non-Executive Director roles with iCare NSW, Clayton Utz, GBST Holdings Limited, The Smith Family and Sigma Healthcare Limited. She is member of risk committee
Mr Mark Haberlin Non-Executive Director Apr 2021
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is chair of risk committee. Other directorships include Layby Group Holdings Limited, April 2020 - present.
Ms Melinda Leigh McGrath Chief Executive OfficerExecutive Director Dec 2020
Ms McGrath has more than 30 years of experience in healthcare with over 25 years of experience in chief executive roles and over 15 years of experience in pathology CEO roles. Melinda has led the organisation's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Melinda was Chief Executive Officer of QML Pathology (part of Healius/Primary Healthcare) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held transformative chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services and a superannuation fund, UC Super.
Ms Sarah Butler Non-Executive Director Feb 2025
Ms Butler has experience in health, insurance, government, consumer and technology industries with a career in strategy consulting with Booz & Company and subsequently at PwC. Sarah has worked as a strategic advisor in more than 30 countries, including 5 years spent living and working in China and Asia. Sarah is currently a non-executive director of Lumonus (global healthtech), Insurance Manufacturers of Australia (being a joint venture of IAG and RACV) and The George Institute for Global Health, where she is also the Chair of the People Committee. Sarah is a member of Chief Executive Women.
Mr Grant Jeffery Non-Executive Director Feb 2025
Mr Jeffery has experience in in healthcare, aerospace and security services, across public and private companies, having held multiple CEO roles across international businesses based in New York, Singapore, California and Sydney. Prior to his corporate career, Grant served as an Officer in the Royal Australian Air Force for 10 years holding leadership roles across various functional disciplines. Grant is currently the Chair and non-executive director of Brighter Life Group and an executive director of BGI Advisory Services as well as a Board advisor to Dokotela.
Ms Eleanor Padman Company Secretary
-
Eleanor Padman Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 52,928,564 26.22%
J P Morgan Nominees Australia Pty Limited 40,768,093 20.20%
HSBC Custody Nominees (Australia) Limited i 23,098,892 11.44%
National Nominees Limited 19,505,294 9.66%
Neweconomy Com Au Nominees Pty Limited 5,563,328 2.76%
Warbont Nominees Pty Ltd 4,488,571 2.22%
BNP Paribas Noms (Nz) Ltd 4,381,212 2.17%
BNP Paribas Nominees Pty Ltd 2,282,496 1.13%
Melinda McGrath 2,173,867 1.08%
ECapital Nominees Pty Limited 2,012,539 1.00%
UBS Nominees Pty Ltd 1,965,408 0.97%
HSBC Custody Nominees (Australia) Limited ii 1,864,257 0.92%
ACL Employee Share Trusco Pty Ltd 1,445,624 0.72%
First Samuel Ltd ACN 086243567 1,273,234 0.63%
HSBC Custody Nominees (Australia) Limited Gsco Eca 1,254,600 0.62%
Hsbc Custody Nominees (Australia) Limited-Gsi Eda 1,225,450 0.61%
Mr Nicholas Barry Debenham & Mrs Annette Cecilia Debenham 1,010,800 0.50%
Zachary Investments Pty Ltd 1,000,000 0.50%
BNP Paribas Noms Pty Ltd 829,947 0.41%
HSBC Custody Nominees (Australia) Limited A/C 2 790,918 0.39%

Profile

since

Note